NR3C2 and hydrops fetalis: In a previous study, the rates of ACE-I/ARBs, beta-blockers, and mineralocorticoid receptor antagonists used in the outpatient population with HF with reduced LVEF were 90.5%, 87.8%, and 42.7%, respectively, but the number of patients using drugs at the target dose was below 50%,15 whereas the same rates were 82.3%, 90.1%, and 74.4%, respectively, in our study.